Navigation Links
Synthetic Genomics Inc. Appoints Joseph Mahler as Chief Financial Officer
Date:6/15/2011

LA JOLLA, Calif., June 15, 2011 /PRNewswire/ -- Synthetic Genomics, Inc. (SGI), a privately held company applying genomic-driven commercial solutions to a variety of global needs including clean renewable energy, new food sources, and medicines, today announced that Joseph Mahler will join the company as Chief Financial Officer (CFO), effective June 18, 2011. Mahler will be responsible for leading and directing all financial aspect of the company. He will report directly to J. Craig Venter, Ph. D., SGI Founder and CEO.

"Joe has had an impressive career directing the financial and corporate strategy for public and private companies," said Dr. Venter. "I am extremely pleased to have him join the SGI management team to help us through the next exciting growth phase of our company. Joe has strong, demonstrated financial skills, coupled with a proven ability to translate cutting-edge technology into revenue-generating business."

Mahler joins SGI from FuelCell Energy Inc, a publicly-traded developer and manufacturer of ultra-clean stationary fuel cell power plants, where he had been employed since 1998. Mahler played a leading role at the company as Senior Vice-President, CFO, Corporate Treasurer and Secretary. In these roles he raised more than $500 million from seven public offerings. He was also instrumental in helping shape the company's business strategy as they grew from 120 employees to more than 400 and expanded operations to serve global markets in Europe and Asia.

Prior to his employment with FuelCell Energy, Mahler was the VP and CFO for Earthgro Inc. where he worked closely with the CEO and management to significantly increase sales and profitability. Earlier in his career, he was a partner with the accounting firm Ernst & Young and other predecessor firms and was employed from 1974 to 1992.

Mahler received a Bachelor of Science degree in accounting from Boston College in 1974, and his certification as a public accountant in 1978.  

About Synthetic Genomics Inc.
SGI, a privately held company founded in 2005, is dedicated to developing and commercializing genomic-driven solutions to address global challenges. SGI's research advances present limitless opportunities for commercial applications in a variety of industries. The Company's main research and business programs are currently focused on the following areas: harnessing photosynthetic organisms to produce value added products (including next generation biofuels, food and feed products) directly from sunlight and carbon dioxide; developing new biological solutions to increase production and/or recovery rates of subsurface hydrocarbons, and creating tools and technologies to advance the field of synthetic genomics. For more information go to: www.syntheticgenomics.com.

Media contact:
Heather Kowalski, hkowalski@syntheticgenomics.com, 858-361-0466


'/>"/>
SOURCE Synthetic Genomics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. WuXi PharmaTech Promotes Dr. Rujian Ma to VP of Synthetic Chemistry
2. The MathWorks Sponsors iGEM Competition for Synthetic Biology at MIT : MATLAB and SimBiology Help Accelerate Design of Synthetic Biological Systems
3. RNAi Helps Illuminate the Inner Workings of the Cell Cycle: Synthetic RNAissance™ Genes Created by DNA2.0 Enable Key Research
4. Synthetic Biology Importance in the 21st Century
5. Synthetic Biology: The Next Biotech Revolution Is Brewing
6. Pepscan Achieves a Breakthrough With CLIPS Immunogen Technology: Synthetic Peptide Antigen is Able to Induce Fully Functional Antibodies Against a Formerly Intractable GPCR Target CXCR7
7. Synthetic Biology on the Rise
8. Does Synthetic Biology Need Synthesized Ethics?
9. Synthetic Genomics Inc. and ExxonMobil Research and Engineering Company Sign Exclusive, Multi-Year Agreement to Develop Next Generation Biofuels Using Photosynthetic Algae
10. Swedish-American Life Science Summit (SALSS) to Address Major Issues Including Healthcare Reform, Synthetic Biology and Innovative Financing for Biotechs
11. Reportlinker Adds Synthetic Biology: Emerging Global Markets Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... CAMBRIDGE, Mass. , Jan. 18, 2017   ... of novel compounds designed to target cancer stemness pathways, ... lead investigational compound, napabucasin, at the 2017 ASCO Gastrointestinal ... San Francisco . Napabucasin is ... pathways by targeting STAT3. i Cancer stem cells ...
(Date:1/18/2017)... ... January 18, 2017 , ... Total Orthopedics and Sports ... A-CIFT™ Solofuse-P™. The operation took place on Wednesday, January 11, 2017 at Long ... an anterior cervical discectomy and fusion on a 42 year old female who ...
(Date:1/18/2017)... ... ... from a new study are stating that if levels of the blood test called ... there is still remaining prostate cancer cells that are more likely to come back, spreading ... an indicator of whether a man’s prostate cancer is growing or not,” stated Dr. ...
(Date:1/18/2017)... , ... January 18, 2017 , ... Thirty-six startup companies ... credits by the Pennsylvania Department of Community and Economic Development in 2016 as part ... located in the University City Keystone Innovation Zone and represent the highest number of ...
Breaking Biology Technology:
(Date:1/6/2017)... JOLLA, Calif. , Jan. 6, 2017 /PRNewswire/ ... 1 safety studies in healthy volunteers of a ... intended to treat acute pancreatitis. ... is typically a mild disorder, but can be ... organ failure and sepsis, where extended hospital stays, ...
(Date:1/3/2017)... , Jan. 3, 2017 Onitor, provider ... introduction of Onitor Track, an innovative biometric data-driven program ... showcasing this month at the 2017 Consumer Electronics Show ... In the U.S., the World Health Organization ... than two-thirds of adults who are overweight or obese. ...
(Date:12/19/2016)... BARCELONA , España y TORONTO , 19 ... fusión con Northern Biologics Inc. que permitirá el desarrollo acelerado de ... ensayos clínicos en varios tipos de tumor en 2017, con múltiples ... ... de su clase con objetivo en el factor inhibidor de leucemia ...
Breaking Biology News(10 mins):